Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway.

PubWeight™: 2.29‹?› | Rank: Top 2%

🔗 View Article (PMID 20421432)

Published in Clin Cancer Res on April 26, 2010

Authors

Laurence Zitvogel1, Oliver Kepp, Laura Senovilla, Laurie Menger, Nathalie Chaput, Guido Kroemer

Author Affiliations

1: INSERM, U1015, and CICBT507, Villejuif, France.

Articles citing this

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy (2016) 7.05

Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37

Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76

A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J (2012) 2.45

Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09

Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med (2012) 1.93

Oncogenic properties of apoptotic tumor cells in aggressive B cell lymphoma. Curr Biol (2015) 1.58

More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol (2011) 1.56

Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget (2014) 1.49

Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther (2013) 1.41

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer (2013) 1.35

Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology (2014) 1.35

Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal (2011) 1.32

The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol (2012) 1.24

Chemoimmunotherapy. Cancer J (2010) 1.13

Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev Clin Immunol (2011) 1.11

Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother (2013) 1.11

Biomarkers and molecular probes for cell death imaging and targeted therapeutics. Bioconjug Chem (2012) 1.10

Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS One (2012) 1.07

ATP release from dying autophagic cells and their phagocytosis are crucial for inflammasome activation in macrophages. PLoS One (2012) 1.03

Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99

Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. Oncogene (2014) 0.97

Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget (2015) 0.96

Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med (2013) 0.95

Wogonin induced calreticulin/annexin A1 exposure dictates the immunogenicity of cancer cells in a PERK/AKT dependent manner. PLoS One (2012) 0.95

Treatment of osteosarcoma with microwave thermal ablation to induce immunogenic cell death. Oncotarget (2014) 0.94

Functional roles of calreticulin in cancer biology. Biomed Res Int (2015) 0.93

Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis (2013) 0.93

Timing the multiple cell death pathways initiated by Rose Bengal acetate photodynamic therapy. Cell Death Dis (2011) 0.91

Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy. Radiat Res (2014) 0.90

Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol (2014) 0.88

Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells. Oncoimmunology (2013) 0.88

The role of soluble CD40L in immunosuppression. Oncoimmunology (2013) 0.88

Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer? Biomed Res Int (2012) 0.87

The Cytotoxicity Mechanism of 6-Shogaol-Treated HeLa Human Cervical Cancer Cells Revealed by Label-Free Shotgun Proteomics and Bioinformatics Analysis. Evid Based Complement Alternat Med (2012) 0.87

Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity. Front Oncol (2012) 0.87

Cellular Mechanism of Newly Synthesized Indoledione Derivative-induced Immunological Death of Tumor Cell. Immune Netw (2011) 0.87

Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines. J Biomed Sci (2011) 0.86

Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Radiat Oncol (2014) 0.86

Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma. Oncotarget (2015) 0.86

Anticancer activity of methyl-substituted oxaliplatin analogs. Mol Pharmacol (2012) 0.84

Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. Br J Cancer (2012) 0.84

Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am J Cancer Res (2011) 0.84

Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget (2015) 0.83

Immune microenvironment in colorectal cancer: a new hallmark to change old paradigms. Clin Dev Immunol (2011) 0.83

Recent advances in therapeutic cancer vaccines. Cancer Biother Radiopharm (2012) 0.83

Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironment via myeloid-derived suppressor cells. Oncotarget (2014) 0.83

Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death Differ (2016) 0.82

Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. Cancer J (2013) 0.82

Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity. Blood Cancer J (2013) 0.82

Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics. Pharmgenomics Pers Med (2015) 0.82

The progression of cell death affects the rejection of allogeneic tumors in immune-competent mice - implications for cancer therapy. Front Immunol (2014) 0.82

Hidden immunotherapy targets challenge dogma. Sci Transl Med (2011) 0.81

Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting. Oncoimmunology (2013) 0.81

Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemo-immunotherapy. Clin Cancer Res (2016) 0.81

Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells. Cancer Gene Ther (2016) 0.80

Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy. Cancer Med (2016) 0.80

The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat Med (2016) 0.80

Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies. J Biomed Biotechnol (2011) 0.80

Human survivin and Trypanosoma cruzi calreticulin act in synergy against a murine melanoma in vivo. PLoS One (2014) 0.79

Type I interferons mediate pancreatic toxicities of PERK inhibition. Proc Natl Acad Sci U S A (2015) 0.79

Immunogenic Cell Death Induced by Ginsenoside Rg3: Significance in Dendritic Cell-based Anti-tumor Immunotherapy. Immune Netw (2016) 0.79

Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. Oncotarget (2016) 0.79

Inflammation and skeletal metastasis. Bonekey Rep (2015) 0.79

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic Virother (2016) 0.79

Chemotherapeutic candidate inducing immunological death of human tumor cell lines. Immune Netw (2012) 0.78

Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress. Mol Cell Oncol (2014) 0.78

Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors. Curr Pharm Biotechnol (2013) 0.78

Novel oncolytic viral therapies in patients with thoracic malignancies. Oncolytic Virother (2016) 0.78

Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma. Oncol Lett (2016) 0.77

Immunogenic cell death due to a new photodynamic therapy (PDT) with glycoconjugated chlorin (G-chlorin). Oncotarget (2016) 0.77

Attenuated mutant strain of Salmonella Typhimurium lacking the ZnuABC transporter contrasts tumor growth promoting anti-cancer immune response. Oncotarget (2015) 0.76

Cryo-ablation improves anti-tumor immunity through recovering tumor educated dendritic cells in tumor-draining lymph nodes. Drug Des Devel Ther (2015) 0.76

Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. Oncogene (2016) 0.75

Nanoemulsion-based mucosal adjuvant induces apoptosis in human epithelial cells. Vaccine (2015) 0.75

Induction of immunogenic cell death of tumors by newly synthesized heterocyclic quinone derivative. PLoS One (2017) 0.75

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Ann Oncol (2017) 0.75

Apoptosis - an Ubiquitous T cell Immunomodulator. J Clin Cell Immunol (2011) 0.75

Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia. Oncoimmunology (2017) 0.75

Three-dimensional culture and interaction of cancer cells and dendritic cells in an electrospun nano-submicron hybrid fibrous scaffold. Int J Nanomedicine (2016) 0.75

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Ann Oncol (2017) 0.75

The cytotoxic synergy of nanosecond electric pulses and low temperature leads to apoptosis. Sci Rep (2016) 0.75

Dynamic changes in immune cell profile in head and neck squamous cell carcinoma: Immunomodulatory effects of chemotherapy. Cancer Sci (2016) 0.75

Immunotherapy with Listeria reduces metastatic breast cancer in young and old mice through different mechanisms. Oncoimmunology (2017) 0.75

The novel immunomodulator IMMUNEPOTENT CRP combined with chemotherapy agent increased the rate of immunogenic cell death and prevented melanoma growth. Oncol Lett (2017) 0.75

Articles by these authors

Autophagy in the pathogenesis of disease. Cell (2008) 34.68

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol (2007) 15.47

The hallmarks of aging. Cell (2013) 14.29

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90

The pathophysiology of mitochondrial cell death. Science (2004) 13.87

Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J (2007) 11.72

Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54

Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27

Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73

Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13

Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99

Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97

Autophagy and aging. Cell (2011) 5.96

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62

Cytoplasmic functions of the tumour suppressor p53. Nature (2009) 5.23

Induction of autophagy by spermidine promotes longevity. Nat Cell Biol (2009) 5.00

Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75

Cell death by necrosis: towards a molecular definition. Trends Biochem Sci (2006) 4.67

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60

Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy (2008) 4.42

An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35

Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32

Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07

The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01

The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci (2005) 3.93

Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82

Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science (2011) 3.74

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41

Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41

Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol (2011) 3.40

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26

Does autophagy contribute to cell death? Autophagy (2005) 3.21

A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21

Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle (2006) 3.21

AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19

BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy (2007) 3.08

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93

Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle (2009) 2.72

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72

Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 2.70

Platelet formation is the consequence of caspase activation within megakaryocytes. Blood (2002) 2.62

Necroptosis: a specialized pathway of programmed necrosis. Cell (2008) 2.61

Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med (2003) 2.56

Autophagy regulation by p53. Curr Opin Cell Biol (2010) 2.56

Can autophagy promote longevity? Nat Cell Biol (2010) 2.55

Cell death assays for drug discovery. Nat Rev Drug Discov (2011) 2.51

Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol (2002) 2.47

The IKK complex contributes to the induction of autophagy. EMBO J (2009) 2.41

Fatty acids trigger mitochondrion-dependent necrosis. Cell Cycle (2010) 2.37

Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response. J Cell Biol (2003) 2.37

Complex inhibitory effects of nitric oxide on autophagy. Mol Cell (2011) 2.36

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med (2005) 2.33

An AIF orthologue regulates apoptosis in yeast. J Cell Biol (2004) 2.33

Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32

Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32

Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol (2012) 2.28

miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res (2010) 2.24

Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J Cell Biol (2011) 2.23

Viral control of mitochondrial apoptosis. PLoS Pathog (2008) 2.21

Nonapoptotic role for Apaf-1 in the DNA damage checkpoint. Mol Cell (2007) 2.20

Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res (2011) 2.16

Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol Cell (2012) 2.14

Alternative cell death mechanisms in development and beyond. Genes Dev (2010) 2.14

Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res (2010) 2.12

Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene (2003) 2.09